FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol

The U.S. Food and Drug Administration announced the approval of the first oral PCSK9 inhibitor, a new medication designed to lower low‑density lipoprotein (LDL) cholesterol in adults with high cholesterol who require additional reduction beyond standard therapy. The drug, identified as an oral PCSK9 inhibitor, received clearance after clinical trials demonstrated a statistically significant decrease in LDL levels compared with placebo, with a safety profile comparable to existing lipid‑lowering treatments. By offering a pill‑based option rather than the injectable formulations that have dominated the PCSK9 inhibitor market, the approval expands therapeutic choices for patients and clinicians seeking more convenient adherence strategies.

The decision follows a comprehensive review of efficacy and safety data submitted by the manufacturer, highlighting the agent’s potential to fill a gap for patients who are unable or unwilling to receive injections. Health officials expect the new oral therapy to complement statins and other lipid‑lowering agents, potentially improving overall cardiovascular risk management. The FDA’s endorsement marks a notable milestone in cholesterol treatment, introducing the first non‑injectable PCSK9 inhibitor to the U.S. market and setting a precedent for future oral biologic developments.